Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.39 |
| ▸ | PARP1 | P09874 | 1/20 | 0.38 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.37 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.37 |
| ▸ | GPR3 | P46089 | 1/20 | 0.35 |
| ▸ | PDE7A | Q13946 | 2/20 | 0.35 |
| ▸ | PDE4A | P27815 | 1/20 | 0.35 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.35 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.35 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.35 |
| ▸ | PDE7B | Q9NP56 | 1/20 | 0.35 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.35 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8404379 | 0.80 | CYP1A2 (0.42) | LMNAHTTGPR3PDK1PDK2 | |
| SCHEMBL17531169 | 0.77 | PDK2 (0.33) | PDK2NR3C1 | |
| SCHEMBL8284885 | 0.77 | KMT2A (0.50) | LMNAHTTPARP1GPR3PKM | |
| SCHEMBL5213745 | 0.77 | IDO1 (0.45) | LMNAHTTGPR3ALDH1A1MEN1 | |
| SCHEMBL27790274 | 0.77 | LMNA (0.36) | LMNAHTTPARP1GPR3PDK1 | |
| SCHEMBL1261718 | 0.77 | ALDH1A1 (0.47) | LMNAHTTALDH1A1MEN1KMT2A | |
| SCHEMBL23002965 | 0.77 | MAPT (0.41) | PDE10APDGFRBPDGFRAALDH1A1KMT2A | |
| SCHEMBL558627 | 0.77 | ADORA2A (0.49) | PDGFRBPDGFRAALDH1A1ADORA2ACYP1A2 | |
| SCHEMBL1810679 | 0.77 | PDGFRB (0.37) | LMNAPDE10APARP1PDGFRBPDGFRA | |
| SCHEMBL10272460 | 0.77 | PDE10A (0.40) | LMNAPDE10APDGFRBPDGFRAPDE7A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160101104-A1 | QUINUCLIDINE COMPOUNDS AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | BRISTOL MYERS SQUIBB CO (US) | 2016-04-14 | — | — | US | disclosed |
| US-20150342935-A1 | QUINUCLIDINE COMPOUNDS AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | BRISTOL MYERS SQUIBB CO (US) | 2015-12-03 | — | — | US | disclosed |
| US-20150094309-A1 | QUINUCLIDINE COMPOUNDS AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | BRISTOL MYERS SQUIBB CO (US) | 2015-04-02 | — | — | US | disclosed |
| US-20140221377-A1 | Quinuclidine Compounds as Alpha-7 Nicotinic Acetylcholine Receptor Ligands | BRISTOL MYERS SQUIBB CO (US) | 2014-08-07 | — | — | US | disclosed |
| US-20100204273-A1 | Quinoline and Quinazoline Derivatives Having Affinity for 5HT1-Type Receptors | GLAXO GROUP LIMITED | 2010-08-12 | — | — | US | disclosed |
| US-7732600-B2 | Quinoline and quinazoline derivatives having affinity for 5HT1-type receptors | GLAXO GROUP LIMITED (GB) | 2010-06-08 | — | — | US | disclosed |
| EP-2145622-A1 | Quinoline and quinazoline derivatives having affinity for 5HT1-type receptors | Glaxo Group Limited (GB) | 2010-01-20 | — | — | EP | disclosed |
| US-20090312546-A1 | QUINOLINE AND QUINAZOLINE DERIVATIVES HAVING AFFINITY FOR 5HT1-TYPE RECEPTORS | GLAXO GROUP LIMITED | 2009-12-17 | — | — | US | disclosed |
| EP-1876174-B1 | Quinoline and quinazoline derivatives having affinity for 5HT1-type receptors | GLAXO GROUP LTD (GB) | 2009-11-11 | — | — | EP | disclosed |
| US-7592346-B2 | e.g. 3-(3-{2-[4-(2-methyl-5-quinolinyl)-1-piperazinyl]ethyl}phenyl)-1,3-oxazolidin-2-one; serotonin receptor antagonist and inverse agonists, agonists or partial agonists, serotonin reuptake inhibitor; antidepressant, anxiolytic agent | GLAXO GROUP LIMITED (GB) | 2009-09-22 | — | — | US | disclosed |
| EP-1480974-A1 | HETEROCYCLYLMETHYLPIPERIDINES AND -PIPERAZINES POSSESSING AFFINITY AT 5HT-1 TYPE RECEPTORS | GLAXO GROUP LIMITED (GB) | 2004-12-01 | — | — | EP | disclosed |
| EP-1480972-A2 | COMPOUNDS POSSESSING AFFINITY AT 5HT1-TYPE RECEPTORS AND USE THEREOF IN THERAPY OF CNS DISORDERS | GLAXO GROUP LIMITED (GB) | 2004-12-01 | — | — | EP | disclosed |
| WO-2004099198-A1 | BENZOXAZINONE DERIVATIVES HAVING AFFINITY FOR 5- HT RECEPTORS, THEIR PREPARATION AND USE | GLAXO GROUP LIMITED (GB) | 2004-11-18 | — | — | WO | disclosed |
| EP-1476444-A1 | HETEROCYCLIC COMPOUNDS POSSESSING AFFINITY AT 5HT1-TYPE RECEPTORS AND USE THEREOF IN THERAPY | GLAXO GROUP LIMITED (GB) | 2004-11-17 | — | — | EP | disclosed |
| EP-1476161-A1 | PIPERIDINE AND PIPERAZINE DERIVATIVES POSSESSING AFFINITY AT 5HT-1 TYPE RECEPTORS | GLAXO GROUP LIMITED (GB) | 2004-11-17 | — | — | EP | disclosed |
| WO-2004046124-A1 | BENZOXAZINONE DERIVATIVES, PREPARATION THEREOF AND USES IN THE TREATMENT OF CNS AND OTHER DISORDERS | GLAXO GROUP LIMITED (GB) | 2004-06-03 | — | — | WO | disclosed |
| WO-2003068236-A1 | PIPERIDINE AND PIPERAZINE DERIVATIVES POSSESSING AFFINITY AT 5HT-1 TYPE RECEPTORS | GLAXO GROUP LIMITED (GB) | 2003-08-21 | — | — | WO | disclosed |
| WO-2003068760-A2 | COMPOUNDS POSSESSING AFFINITY AT 5HT1-TYPE RECEPTORS AND USE THEREOF IN THERAPY OF CNS DISORDERS | GLAXO GROUP LIMITED (GB) | 2003-08-21 | — | — | WO | disclosed |
| WO-2003068772-A1 | HETEROCYCLIC COMPOUNDS POSSESSING AFFINITY AT 5HT1-TYPE RECEPTORS AND USE THEREOF IN THERAPY | GLAXO GROUP LIMITED (GB) | 2003-08-21 | — | — | WO | disclosed |
| WO-2003068771-A1 | HETEROCYCLYMETHYLPIPERIDINES AND -PIPERAZINES POSSESSING AFFINITY AT 5HT-1 TYPE RECEPTORS | GLAXO GROUP LIMITED (GB) | 2003-08-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100204273-A1 | Quinoline and Quinazoline Derivatives Having Affinity for 5HT1-Type Receptors | OPRK1, OPRL1, OPRD1 | LMNA 2269/4885HTT 857/4885PDE10A 1574/4885 |
| US-20140221377-A1 | Quinuclidine Compounds as Alpha-7 Nicotinic Acetylcholine Receptor Ligands | CHRNA7, CHRNA5, CHRNA6 | LMNA 2215/4885HTT 714/4885PDE10A 1526/4885 |
| US-20160101104-A1 | QUINUCLIDINE COMPOUNDS AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | CHRNA7, CHRNA5, CHRNA6 | LMNA 2215/4885HTT 714/4885PDE10A 1526/4885 |
| US-20150342935-A1 | QUINUCLIDINE COMPOUNDS AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | CHRNA7, CHRNA5, CHRNA6 | LMNA 2215/4885HTT 714/4885PDE10A 1526/4885 |
| US-20090312546-A1 | QUINOLINE AND QUINAZOLINE DERIVATIVES HAVING AFFINITY FOR 5HT1-TYPE RECEPTORS | HTR1A, HTR1D, HTR1F | LMNA 1099/4885HTT 997/4885PDE10A 1672/4885 |
| US-20150094309-A1 | QUINUCLIDINE COMPOUNDS AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | CHRNA7, CHRNA5, CHRNA6 | LMNA 2215/4885HTT 714/4885PDE10A 1526/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.